Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 2/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4679314 | 0.85 | GRM5 (0.41) | GRM5CYP11B2 | |
| SCHEMBL4683333 | 0.84 | GRM5 (0.38) | GRM5CYP11B2 | |
| SCHEMBL4678648 | 0.81 | GRM5 (0.44) | GRM5CYP11B2ALDH1A1CYP2C19 | |
| SCHEMBL4679212 | 0.76 | CYP2C19 (0.42) | GRM5ALDH1A1CYP2C19POLB | |
| SCHEMBL4799118 | 0.71 | GRM5 (0.41) | GRM5CYP11B2ALDH1A1CYP2C19POLB | |
| SCHEMBL4698873 | 0.70 | GRM5 (0.74) | GRM5 | |
| SCHEMBL13707060 | 0.69 | CYP2C19 (0.47) | GRM5CYP11B2ALDH1A1CYP2C19POLB | |
| SCHEMBL8283632 | 0.67 | PGR (0.58) | GRM5ALDH1A1CYP2C19POLB | |
| SCHEMBL13706913 | 0.67 | CYP11B2 (0.49) | CYP11B2ALDH1A1CYP2C19 | |
| SCHEMBL4682489 | 0.66 | GRM5 (0.46) | GRM5CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060004001-A1 | Tetrahydroquinolones and their use as modulators of metabotropic glutamate receptors | MERZ PHARMA GMBH & CO., KGAA (DE) | 2006-01-05 | — | — | US | claimed |
| EP-1943247-A1 | TETRAHYDROQUINOLINONES AND THEIR USE AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Merz Pharma GmbH & Co.KGaA (DE) | 2008-07-16 | — | — | EP | disclosed |
| WO-2007023245-A1 | TETRAHYDROQUINOLINONES AND THEIR USE AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2007-03-01 | — | — | WO | disclosed |
| WO-2007023245-A1 | TETRAHYDROQUINOLINONES AND THEIR USE AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2007-03-01 | — | — | WO | disclosed |
| US-20060004001-A1 | Tetrahydroquinolones and their use as modulators of metabotropic glutamate receptors | MERZ PHARMA GMBH & CO., KGAA (DE) | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004001-A1 | Tetrahydroquinolones and their use as modulators of metabotropic glutamate receptors | GRM1, GRM5, GRM2 | GRM5 2/4885CYP11B2 1254/4885ALDH1A1 3118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.